Biocompatible AIEgen/p-glycoprotein siRNA@reduction-sensitive paclitaxel polymeric prodrug nanoparticles for overcoming chemotherapy resistance in ovarian cancer
Conclusion: Our findings demonstrated the Py-TPE/siRNA@PMP as a promising agent for the highly efficient treatment of PTX-resistant cells and overcoming the shortage of chemotherapy in ovarian cancer.
Source: Theranostics - Category: Molecular Biology Authors: Jun Wu, Quan Wang, Xiaoqi Dong, Min Xu, Juliang Yang, Xiaoqing Yi, Biao Chen, Xiyuan Dong, Ying Wang, Xiaoding Lou, Fan Xia, Shixuan Wang, Jun Dai Tags: Research Paper Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Molecular Biology | Nanotechnology | Ovarian Cancer | Ovaries